权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel antimicrobials targeting MDR pathogens from animal microbial symbionts

针对动物微生物共生体中的耐多药病原体的新型抗菌药物

基本信息

批准号：
10592380
负责人：
David R Andes
金额：
$ 595.5万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592380
关键词：
Address Anabolism Animals Anti-Infective Agents Antibiotics Antimicrobial Resistance Bacteria Biological Biological Assay Chemicals Computational Biology Culture Techniques Development Drug resistance Ecology Environment Epidemic Genomics Goals Health Human In Vitro Invertebrates Investigation Lead Libraries Medicine Methods Microbe Microbial Genome Sequencing Mining Minority Natural Compound Natural Products Natural Products Chemistry Pathogenesis Pathway interactions Pharmaceutical Preparations Production Property Public Health Research Resistance Resources Safety Series Soil Source Streptomyces Symbiosis Taxon Techniques Technology Testing Therapeutic Wisconsin Work antimicrobial antimicrobial drug antimicrobial resistant infection clinical development combat drug development drug discovery drug resistant bacteria drug resistant pathogen effective therapy fungus in vivo industry partner innovation insight marine metabolomics microbial microbiome multi-drug resistant pathogen multidisciplinary natural antimicrobial next generation novel novel therapeutics pathogen pathogenic bacteria pathogenic fungus pre-clinical preclinical study scaffold secondary metabolite small molecule success symbiont theories

项目摘要

Project Summary The discovery of new antimicrobials has failed to keep pace with the emergence of antimicrobial-resistant infections, threatening public health. The overarching goal of the Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. Based upon our preliminary investigations using interdisciplinary, cutting-edge approaches, we hypothesize that natural products from animal-microbe symbioses represent a new paradigm in antimicrobial drug discovery. The Center proposes innovative conceptual and technical advances to overcome the critical bottlenecks of traditional antimicrobial discovery to deliver therapeutic countermeasures for the drug-resistance epidemic. Relevance There is an ever-present and growing need to find novel, effective therapies for emerging resistant pathogens that are becoming an increasing threat to the public health. The goals of the Center are to discover new antimicrobial drugs. Our collaborative effort focuses on high-value natural products produced by under- explored sources of biological and chemical diversity.

项目摘要新的抗菌药物的发现未能跟上耐药性的出现。感染，威胁公共卫生。威斯康星州抗菌药物发现和发展中心的任务是制定治疗对策，以应对抗菌素耐药性危机。基于我们使用跨学科、尖端方法的初步调查，我们假设，来自动物-微生物共生体的天然产物代表了抗微生物药物发现的新范例。的中心提出创新的概念和技术进步，以克服传统的关键瓶颈，抗菌剂的发现，以提供耐药性流行病的治疗对策。相关性对于新出现的耐药病原体，寻找新的有效疗法的需求一直存在且不断增长对公众健康的威胁越来越大该中心的目标是发现新的抗微生物药物我们的合作重点是高价值的天然产品生产的下，探索生物和化学多样性的来源。